Lotiglipron

CAS No. 2401892-75-7

Lotiglipron( —— )

Catalog No. M37118 CAS No. 2401892-75-7

Lotiglipron (PF-07081532) is an orally active, potent GLP-1R agonist that reduces blood glucose and body weight, potentially aiding in the study of type 2 diabetes mellitus (T2DM) and obesity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 97 In Stock
5MG 136 In Stock
10MG 207 In Stock
25MG 403 In Stock
50MG 605 In Stock
100MG 888 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lotiglipron
  • Note
    Research use only, not for human use.
  • Brief Description
    Lotiglipron (PF-07081532) is an orally active, potent GLP-1R agonist that reduces blood glucose and body weight, potentially aiding in the study of type 2 diabetes mellitus (T2DM) and obesity.
  • Description
    Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    Glucagon Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2401892-75-7
  • Formula Weight
    575.05
  • Molecular Formula
    C31H31ClN4O5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (217.37 mM; Ultrasonic )
  • SMILES
    C[C@]1(OC2=C(C=CC=C2O1)C3CCN(CC=4N(C[C@@H]5CCO5)C=6C(N4)=CC=C(C(O)=O)C6)CC3)C7=CC=C(Cl)C=N7
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Buckeridge C, et al. Once-daily oral small molecule GLP-1R agonist PF-07081532 reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity. Hybrid 58th EASD Annual Meeting; Sept 19–23, 2022 (abstr 114).
molnova catalog
related products
  • PF-06882961 Tris

    PF-06882961 Tris is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist.

  • Taspoglutide

    Taspoglutide is a glucagon-like peptide-1(GLP-1) agonist for treatment of type 2 diabetes.

  • GLP-1R modulator C5

    GLP-1R modulator C5 is a small molecule GLP-1R orthosteric modulator that enhances GLP-1 binding to GLP-1R via transmembrane sites and can be used in the study of type II diabetes.